-
WSP-5 for Live-Cell H2S Imaging
2026-09-15
WSP-5 combines rapid turn-on fluorescence with live-cell compatibility to reveal where and when hydrogen sulfide changes occur. Its workflow can extend bulk H2S measurements into spatial assays for cardiomyocyte stress, donor-compound testing, and cancer cell model imaging.
-
MDL 28170 Calpain Inhibitor: Research Workflows
2026-09-15
MDL 28170 is a cell-permeable calpain inhibitor suited to mechanistic neuroprotection research, apoptosis assays, and injury models in which intracellular cysteine proteases become overactive. This guide translates recent BDNF/TrkB findings into practical assay design, dosing logic, controls, and troubleshooting strategies.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-09-14
Masitinib (AB1010), SKU A2942, provides a DMSO-compatible reference compound for focused KIT, PDGFRα, PDGFRβ, mast-cell, and selected GIST research. It is not appropriate for protocols requiring aqueous or ethanol solubility, broad-spectrum kinase inhibition, or clinical treatment decisions.
-
CAY10499: HSL and MGL Inhibitor for Lipid Research
2026-09-14
CAY10499 is an inhibitor of human hormone sensitive lipase and monoglyceride lipase for controlled lipid-metabolism experiments. Supplier-reported IC50 values support its use as a lipid metabolism assay reagent, while its activity against FAAH requires careful selectivity controls.
-
Glycogen Colorimetric Assay Kit II for Metabolic Studies
2026-09-13
The Glycogen Colorimetric Assay Kit II converts tissue glycogen into a measurable glucose-linked color signal, supporting interference-aware studies in liver, muscle, diabetes, and exercise biology. Its workflow is especially useful for separating glycogen abundance from training efficiency, circadian performance, and fuel utilization.
-
Foretinib: From Kinase Potency to Translational Proof
2026-09-12
Foretinib (GSK1363089) offers a powerful framework for connecting Met and VEGFR pathway inhibition with tumor cell growth inhibition, motility, invasion, and metastasis. This thought-leadership guide shows how translational researchers can turn multikinase potency into more informative, mechanistically resolved cancer studies.
-
α7nAChR, Pyroptosis, and HIV-1 BBB Breakdown
2026-09-12
A 2026 study identifies α7nAChR-dependent pyroptosis in brain microvascular endothelial cells as a mechanism linking HIV-1 gp120 exposure to blood–brain barrier disruption. Its mapping of an α7nAChR/ROS/NF-κB/NLRP3 pathway, together with protection by memantine and metformin, provides a mechanistic basis for further drug-repurposing studies in HIV-associated neurocognitive disorder.
-
40-Hz Flicker, MHC-II+ Microglia, and Retinal Aβ
2026-09-11
A 2026 IOVS study reports that 40-Hz light flicker increases MHC-II expression and microglial activity in aged mouse retinas, enhancing clearance of experimentally deposited amyloid-β oligomers. The intervention also improved retinal electrophysiology and visual behavior, while pharmacological microglial inhibition eliminated these benefits, supporting a microglia-dependent mechanism that still requires validation in spontaneous and human retinal disease.
-
Cardamomin in Oxidative Damage and Ischemic Stroke
2026-09-11
The reference study links cardamomin from Amomum villosum stems and leaves with protection against hydrogen peroxide-induced oxidative injury and permanent cerebral ischemia. Its key contribution is a mechanistic model involving MEK/ERK-dependent NRF2 activation, suppression of oxeiptosis and parthanatos, and preservation of brain tissue in a rat stroke model.
-
Cefiderocol Activity in Resistant European Non-Fermenters
2026-09-10
A large European surveillance study directly compared cefiderocol with contemporary β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and ceftolozane-tazobactam. Its integrated susceptibility and genomic analysis supports early parallel testing of cefiderocol and other active options, while also showing why in vitro activity should not be equated with clinical efficacy.
-
CCK8 in Translational TNBC: From Signal to Strategy
2026-09-10
Mitochondrial RNA polymerase, or POLRMT, is emerging as a mechanistically attractive target in triple-negative breast cancer, but mitochondrial interventions also create a measurement challenge. This thought-leadership article explains how Cell Counting Kit-8 (CCK-8) can connect metabolic perturbation with proliferation, viability, and cytotoxicity while showing why its signal should be interpreted alongside orthogonal endpoints. The discussion moves beyond a conventional product overview toward a translational framework for experimental design, resistance analysis, and oncology decision-making.
-
MK-5108 (VX-689): AURKA Assay Design
2026-09-09
MK-5108 (VX-689) enables selective Aurora A perturbation studies that connect retinoblastoma pathology with functional cancer models. This guide explains how to interpret biochemical potency, cell-cycle phenotypes, and xenograft responses without confusing AURKA overexpression with proven tumor dependence.
-
Tamsulosin for Reproducible Cell Assays
2026-09-09
This scenario-driven guide explains how Tamsulosin (SKU C6445) can support controlled α1A-adrenergic receptor experiments without confusing receptor pharmacology with nonspecific cytotoxicity. It covers assay design, solvent compatibility, protocol optimization, data interpretation, and practical vendor-selection criteria for biomedical laboratories.
-
Anlotinib and VEGFR2-Driven Tumor Angiogenesis
2026-09-08
The reference study established anlotinib as a highly potent, orally active, and comparatively selective VEGFR2 inhibitor whose antitumor activity was primarily linked to suppression of tumor angiogenesis. Its integrated biochemical, endothelial, ex vivo vascular, and xenograft experiments provide a useful framework for interpreting migration, tube formation, vascular-density, and tumor-growth endpoints.
-
Silybin A: A Translational Strategy for Liver Research
2026-09-08
Silybin A can serve as a chemically defined tool for connecting redox, inflammatory, autophagy, and metastatic phenotypes in liver research. This thought-leadership guide explains how to move beyond generic Silymarin claims by controlling identity, solubility, assay design, and mechanistic validation.